First look at our novel research findings in #LongCOVID and #MECFS:
Our initial data shows elevated Arginase-1 (ARG1) in many patients compared to HC. While we need more control data for statistical significance, this pattern aligns with known disease mechanisms and symptoms 🧵
Amatica Health
69 posts
Patient-centred chronic disease research
Joined August 2023
- 🔬Alterations in serum PINK1 in ME/CFS & LC PINK1 acts as a 'quality control sensor', accumulating on damaged mitochondria to trigger removal and recycling (called mitophagy) - Elevated vs reference control (p=0.0171) - Distinct high/low pattern - Points to patient subgroups
- Who we are: ME/CFS patient researchers (mostly COVID-triggered) We are working to bring patients the tests they need to understand their disease Our goal is to drive research forward towards diagnostic biomarkers and personalised treatments
- We’re so excited to release the next Amatica Health project: Whole blood RNA sequencing 20,000 gene expression results. 1,500 biological pathways. All in one test amaticahealth.com/me-cfs-long-co…
- Clustering of energy, metabolic & O2-sensing markers reveals two distinct patient groups in Long COVID/ME/CFS The group with more abnormal energy/metabolic/O2-sensing shows significant alterations in inflammatory signalling & vascular regulation pathways
- 🔬New insights from LC/MECFS similarity networks We mapped 31 biomarkers across mitochondrial, immune, vascular, redox, and neuroinflammation pathways Natural clusters emerge linking patients who truly share biology—and separating those who don't A step towards precision care
- Replying to @amaticahealth🔬 Future treatment implications: ARG1 inhibitors currently in cancer trials could potentially be explored for LC/ME patients with elevated ARG1 We plan to work with clinicians on investigating compassionate use pathways once these drugs complete safety trials
- Replying to @amaticahealthARG1 (Arginase-1) is an enzyme that breaks down L-arginine, affecting NO production and immune function Overexpression creates a cascade of effects across multiple systems - from blood vessels to brain function. In LC and MECFS, elevated ARG1 could contribute to many symptoms
- Replying to @amaticahealthHelp advance LC & MECFS research while gaining insight into your own condition Register to join batches 2&3 here: amaticahealth.com/me-cfs-long-co… Our goal: Analyse hundreds of samples to understand rare subgroups and symptom associations Follow @amaticahealth for research updates
- Replying to @amaticahealthBy combining detailed symptom questionnaires with molecular data (like ARG1), we aim to understand what drives disease subtypes in #LongCOVID & #MECFS This will help match patients to treatments and improve trial success through better subgroup identification 🧬🔍
- Announcing our Long COVID and ME/CFS questionnaire platform alpha release We aim to map every symptom & history layer to resolve hidden sub-groups—enabling precision diagnostics and personalised care Seeking alpha testers to help refine it: my.amaticahealth.com/alpha
- Replying to @amaticahealthHelp advance LC & MECFS research while gaining insight into your own condition Register to join batches 2&3 here: amaticahealth.com/pages/31-marke… Our goal: Analyse hundreds of samples to understand rare subgroups Follow @amaticahealth for research updates
- Replying to @amaticahealth📈 More insights coming soon! With 27 markers still to analyse & recruitment open for new batches, we're building a dataset to unlock connections between symptoms & molecular signatures
- Orignal Research 🔬📷 47% of ME/CFS patients showed elevated α-NAGA (nagalase) levels compared to controls Although the overall difference wasn’t statistically significant (p=0.1704), we will focus analysis within this subgroup & expand the study with more participants📷🧵













